Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the GO ASIA initiative
Alimentary Pharmacology & Therapeutics2018Vol. 47(6), pp. 816–825
Citations Over TimeTop 10% of 2018 papers
Wah‐Kheong Chan, Sombat Treeprasertsuk, Kento Imajo, Atsushi Nakajima, Yosuke Seki, Kazunori Kasama, Satoru Kakizaki, Jian‐Gao Fan, Myeong Jun Song, Seolah Yoon, Yock Young Dan, Laurentius Lesmana, Khek Yu Ho, Khean‐Lee Goh, Vincent Wai‐Sun Wong
Abstract
More severe liver disease can be suspected or ruled out based on factors identified in this study. Utilisation of structured lifestyle program, vitamin E and pioglitazone was limited despite this being a cohort of biopsy-proven NAFLD patients with majority of patients having NASH.
Related Papers
- → Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease(2017)30 cited
- → Prevalence of fatty liver in metabolic syndrome(2020)16 cited
- → Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?(2008)17 cited
- → Features of myocardial damage indexes in patients with metabolic syndrome and nonalcoholic fatty liver disease(2022)1 cited
- → Preventive effect of pioglitazone against nonalcoholic fatty liver disease in Sprague-Dawley rats and its mechanism(2009)1 cited